MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

Core Insights - MaxCyte has signed a Strategic Platform License agreement with Moonlight Bio to utilize its Flow Electroporation technology and ExPERT™ platform for T cell therapy development [1][2][3] - The partnership aims to enhance the scalability and efficiency of Moonlight Bio's gene-edited T cell therapies, particularly targeting solid tumors [2][3][5] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing cell-based therapeutics through its Flow Electroporation technology and SeQure™ gene editing services [4] - The company has over 25 years of experience in cell engineering and aims to empower researchers globally to develop safe and effective treatments [4] Moonlight Bio's Objectives - Moonlight Bio is a preclinical-stage biotechnology company dedicated to developing enhanced T cell therapies for cancer patients, particularly for solid tumors [5] - The company seeks to overcome the limitations of current therapies that fail to provide durable responses in solid tumor treatments [5]